These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

533 related articles for article (PubMed ID: 16728573)

  • 1. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature.
    Fugazzola L; Puxeddu E; Avenia N; Romei C; Cirello V; Cavaliere A; Faviana P; Mannavola D; Moretti S; Rossi S; Sculli M; Bottici V; Beck-Peccoz P; Pacini F; Pinchera A; Santeusanio F; Elisei R
    Endocr Relat Cancer; 2006 Jun; 13(2):455-64. PubMed ID: 16728573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
    Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
    Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High prevalence of B-RAF mutation in papillary carcinoma of the thyroid in north-east Italy.
    Girlando S; Cuorvo LV; Bonzanini M; Morelli L; Amadori P; Dalla Palma P; Barbareschi M
    Int J Surg Pathol; 2010 Jun; 18(3):173-6. PubMed ID: 20460314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF mutations in an Italian cohort of thyroid cancers.
    Fugazzola L; Mannavola D; Cirello V; Vannucchi G; Muzza M; Vicentini L; Beck-Peccoz P
    Clin Endocrinol (Oxf); 2004 Aug; 61(2):239-43. PubMed ID: 15272920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of BRAF (V600E) mutation and Ki-67 labeling index in papillary thyroid carcinomas.
    Nakayama H; Yoshida A; Nakamura Y; Hayashi H; Miyagi Y; Wada N; Rino Y; Masuda M; Imada T
    Anticancer Res; 2007; 27(5B):3645-9. PubMed ID: 17972530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas.
    Puxeddu E; Moretti S; Elisei R; Romei C; Pascucci R; Martinelli M; Marino C; Avenia N; Rossi ED; Fadda G; Cavaliere A; Ribacchi R; Falorni A; Pontecorvi A; Pacini F; Pinchera A; Santeusanio F
    J Clin Endocrinol Metab; 2004 May; 89(5):2414-20. PubMed ID: 15126572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The presence of BRAF point mutation in adult papillary thyroid carcinomas from atomic bomb survivors correlates with radiation dose.
    Takahashi K; Eguchi H; Arihiro K; Ito R; Koyama K; Soda M; Cologne J; Hayashi Y; Nakata Y; Nakachi K; Hamatani K
    Mol Carcinog; 2007 Mar; 46(3):242-8. PubMed ID: 17186541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRAF mutations are associated with some histological types of papillary thyroid carcinoma.
    Trovisco V; Vieira de Castro I; Soares P; Máximo V; Silva P; Magalhães J; Abrosimov A; Guiu XM; Sobrinho-Simões M
    J Pathol; 2004 Feb; 202(2):247-51. PubMed ID: 14743508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas: correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genes.
    Oler G; Cerutti JM
    Cancer; 2009 Mar; 115(5):972-80. PubMed ID: 19152441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan.
    Liu RT; Chen YJ; Chou FF; Li CL; Wu WL; Tsai PC; Huang CC; Cheng JT
    Clin Endocrinol (Oxf); 2005 Oct; 63(4):461-6. PubMed ID: 16181240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathologic features and BRAF(V600E) mutation analysis in cutaneous metastases from well-differentiated thyroid carcinomas.
    Erickson LA; Jin L; Nakamura N; Bridges AG; Markovic SN; Lloyd RV
    Cancer; 2007 May; 109(10):1965-71. PubMed ID: 17387744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)).
    Carta C; Moretti S; Passeri L; Barbi F; Avenia N; Cavaliere A; Monacelli M; Macchiarulo A; Santeusanio F; Tartaglia M; Puxeddu E
    Clin Endocrinol (Oxf); 2006 Jan; 64(1):105-9. PubMed ID: 16402937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of correlation between BRAF V600E mutational status and the expression profile of a distinct set of miRNAs in papillary thyroid carcinoma.
    Sheu SY; Grabellus F; Schwertheim S; Handke S; Worm K; Schmid KW
    Horm Metab Res; 2009 Jun; 41(6):482-7. PubMed ID: 19370505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF (V600E) mutation analysis in papillary thyroid carcinomas by peptide nucleic acid clamp real-time PCR.
    Jeong D; Jeong Y; Park JH; Han SW; Kim SY; Kim YJ; Kim SJ; Hwangbo Y; Park S; Cho HD; Oh MH; Yang SH; Kim CJ
    Ann Surg Oncol; 2013 Mar; 20(3):759-66. PubMed ID: 23179992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma.
    Baitei EY; Zou M; Al-Mohanna F; Collison K; Alzahrani AS; Farid NR; Meyer B; Shi Y
    J Pathol; 2009 Apr; 217(5):707-15. PubMed ID: 19156774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of molecular markers and tumor histological type in central lymph node metastasis of papillary thyroid carcinoma.
    Paulson L; Shindo M; Schuff K; Corless C
    Arch Otolaryngol Head Neck Surg; 2012 Jan; 138(1):44-9. PubMed ID: 22249628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF(V600E) mutation and the biology of papillary thyroid cancer.
    Frasca F; Nucera C; Pellegriti G; Gangemi P; Attard M; Stella M; Loda M; Vella V; Giordano C; Trimarchi F; Mazzon E; Belfiore A; Vigneri R
    Endocr Relat Cancer; 2008 Mar; 15(1):191-205. PubMed ID: 18310287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid Rodolico V; Cabibi D; Pizzolanti G; Richiusa P; Gebbia N; Martorana A; Russo A; Amato MC; Galluzzo A; Giordano C
    Cancer; 2007 Sep; 110(6):1218-26. PubMed ID: 17685465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAF mutation and RASSF1A expression in thyroid carcinoma of southern Italy.
    Santoro A; Pannone G; Carosi MA; Francesconi A; Pescarmona E; Russo GM; Feola A; Losito S; Franco R; Nappi L; Aquino G; De Rosa G; Di Domenico M; Bufo P
    J Cell Biochem; 2013 May; 114(5):1174-82. PubMed ID: 23192464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma.
    Kim TY; Kim WB; Rhee YS; Song JY; Kim JM; Gong G; Lee S; Kim SY; Kim SC; Hong SJ; Shong YK
    Clin Endocrinol (Oxf); 2006 Sep; 65(3):364-8. PubMed ID: 16918957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.